Filippo Gallina, Thoracic Surgeon at IRCCS National Cancer Institute of Rome, shared a paper he and his colleagues authored on X:
“Establishing survival benchmarks in the era of peri-operative immunotherapy.
Neoadjuvant/peri-op chemo-IO improves OS vs historical controls in resectable NSCLC
Jonathan Spicer, Medical Director of the McGill Thoracic Oncology Program shared this post, adding:
“Important work! Hopefully those who believe that the neoadj/periop trials were lacking the control of up front surgery will be reassured that it was indeed appropriate to select neoadj chemo+surgery as the control for all those trials. Always a joy to collaborate with Filippo Gallina.”
Establishing survival benchmarks in the era of peri-operative immunotherapy
Authors: Filippo Tommaso Gallina et al.
